Feb 26, 2009
Lytix Biopharma to expand team of drug development professionals

8 new job openings. We will expand our team of drug development professionals in support of the clinical development of two novel drugs.

Lytix Biopharma develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments.  These therapeutic areas have a high unmet medical need, and Lytix Biopharma is in a unique position to develop drugs that fulfill these needs. The Company was established in 2003 to commercialise world-class research in the field of lytic peptides spun out by the founding scientists working in the University Hospital and University of Tromsø in Norway.

According to Lytix Biopharma CEO Gunnar Sælid, “The Company is rapidly moving into clinical development phases for two important projects; LTX-109, a novel antimicrobial compound and LTX-315 (OncoporeTM), a first-in-class treatment of solid tumours.  Both these compounds are scheduled to enter the clinical phases during the latter half of 2009. In order to strengthen our drug development team and ensure the execution of an efficient clinical development strategy, the Company is seeking to attract individuals whom can contribute in a significant way to our future drug development activities. Despite the global down-turn in the economy, we are in the privileged position of being well-funded. Adverts have been placed in leading Scandinavian newspapers and we are using our network of contacts to identify potential candidates for the open positions which include project managers, clinical development managers, QA and regulatory managers as well as a cancer immunologist.”